Comparative trial of sclerotherapy for hydroceles.
We present a prospective single-blind trial of sclerotherapy for hydroceles with tetradecyl sulphate and rolitetracycline as sclerosants. Twenty-seven hydroceles were treated with tetradecyl sulphate and 28 with rolitetracycline. The median follow-up was 13 months. There were no statistically significant differences between the 2 drugs in respect of cure rate and complications. The overall cure rate for both drugs was 96%. Complications were rare and common to both drugs. Tetradecyl sulphate and rolitetracycline were found to be equally effective as sclerosants.
Rencken
R K
RK
Department of Urology, Medical University of Southern Africa.
Bornman
M S
MS
Reif
S
S
Olivier
I
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012597:Sclerosing Solutions; D015911:Sclerotherapy; D016037:Single-Blind Method; D012981:Sodium Tetradecyl Sulfate; D006848:Testicular Hydrocele / Q000628:therapy*
D012597:Sclerosing Solutions; D012981:Sodium Tetradecyl Sulfate